Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Outlook on the AI-based Drug Discovery Global Market to 2035 – Industry Trends and Forecasts

Published

on

Dublin, May 12, 2022 (GLOBE NEWSWIRE) — The “AI-based Drug Discovery Market: Distribution by Drug Discovery Steps, Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current landscape and future potential of the players engaged in offering AI-based services, platforms and tools for the discovery of novel drug candidates. The study features an in-depth analysis, highlighting the capabilities of AI-based drug discovery service / technology providers.

The discovery and development process of a novel therapeutic candidate is often tedious and fraught with several challenges. The key concern associated with the overall process is the high attrition rate, which is often attributed to the trial-and-error approach followed for the drug discovery process. In fact, only a small proportion of pharmacological leads are translated into viable product candidates for clinical studies. In addition, experts believe that close to 90% of the product candidates considered in such studies fail to advance further in the development process.

This, in turn, often results in a massive financial burden. In this context, it is estimated that a prescription drug takes around 10 to 15 years and an average investment of USD 1 to 2 billion, in order to traverse from the bench to the market. Moreover, around one-third of the aforementioned expenditure is incurred during the drug discovery phase alone. Therefore, to address the existing concerns, such as rising capital requirements and failure of late-stage programs, pharmaceutical players are currently exploring the implementation of Artificial Intelligence (AI) based tools to better inform their discovery and development operations, using available chemical and biological data.

Specifically, AI is believed to be capable of processing and analyzing large volumes of clinical / medical data, as well as leverage it to better inform modern drug discovery efforts. In this context, deep learning algorithms have been demonstrated to be able to cross-reference published scientific literature (structured data) with electronic health records (EHRs) and clinical trial information (unstructured data), in order to generate actionable insights for target identification, hit generation and lead optimization.

At present, machine learning, deep learning, supervised learning, unsupervised learning and natural language processing are some of the key AI-based tools being deployed across different processes, including drug discovery, within the healthcare sector. The use of AI-enabled technologies in drug discovery operations is expected to not only improve the overall R&D productivity, but also reduce clinical failure of product candidates, by enabling accurate prediction of its safety and efficacy during early stages of development. Close to 210 companies currently claim to offer AI-based services, platforms and tools for drug discovery.

Further, over USD 10 billion has been invested in this market by both private and public sector investors, in the last five years. Interestingly, close to 50% of the aforementioned amount was invested in the last two years, reflecting the increasing interest of stakeholders in AI-based tools for drug discovery.

Additionally, close to 440 recently instances of collaborations have been reported between industry / academic stakeholders in order to advance the development of various AI-based solutions for drug discovery. Considering the active initiatives being undertaken by players based in this domain, we are led to believe that the opportunity for stakeholders in this niche, albeit upcoming, industry is likely to grow at a commendable pace in the foreseen future.

Amongst other elements, the report features:

  • A detailed overview of the overall landscape of companies offering AI-based services, platforms and tools for drug discovery, along with information on several relevant parameters, such as their year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific and Rest of the World) and type of company (service providers, technology providers and in-house players). The chapter also covers details related to the type of AI technology (artificial intelligence (undefined), deep learning, machine learning (undefined), natural language processing, data science, reinforcement learning, supervised learning and unsupervised learning), drug discovery steps (target discovery / identification / validation, lead identification / optimization / generation and ADME / toxicity testing), type of drug molecule (small molecules, biologics and both) and target therapeutic area (oncological disorders, neurological disorders, infectious diseases, immunological disorders, cardiovascular disorders, rare diseases, metabolic disorders, respiratory disorders, gastrointestinal disorders, musculoskeletal disorders, dermatological disorders, hematological disorders, ophthalmic disorders and other disorders).
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in AI-based drug discovery domain, across North America, Europe and Asia-Pacific. Each profile provides an overview of the company, featuring information on the year of establishment, number of employees, location of their headquarters, key executives, details related to its AI-based drug discovery technology portfolio, recent developments and an informed future outlook.
  • An analysis of partnerships inked between stakeholders engaged in this domain, during the period 2009-2022, covering research and development agreements, technology access / utilization agreements, acquisitions, technology licensing agreements, joint ventures / mergers, technology integration agreements, service agreements and other related agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, target therapeutic area, focus area, type of partner company and most active players (in terms of number of partnerships). It also highlights the regional distribution of the partnership activity witnessed in this market.
  • A detailed analysis of various investments, such as grants, awards, seed financing, venture capital financing, debt financing, capital raised from IPOs and subsequent offerings, that were undertaken by players engaged in this domain, during the period 2006-2022.
  • An in-depth analysis of the various patents that have been filed / granted related to AI-based drug discovery technologies, from 2019 to February 2022, taking into consideration parameters, such as application year, geographical region, CPC symbols, emerging focus areas, type of applicant and leading players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of drug developers, bargaining power of AI-based drug discovery companies, threats of substitute technologies and rivalry among existing competitors.
  • An elaborate valuation analysis of companies that are involved in the AI-based drug discovery market, based on our proprietary, multi-variable dependent valuation model to estimate the current valuation / net worth of industry players.
  • An insightful analysis highlighting the likely cost saving potential associated with the use of AI in the drug discovery sector, based on information gathered from close to 15 countries, taking into consideration various parameters, such as pharmaceutical R&D expenditure, drug discovery expenditure / budget and adoption of AI across various drug discovery steps.

Key Questions Answered

  • Who are the leading players engaged in the AI-based drug discovery market?
  • Which of the key AI technologies are presently being most commonly adopted by drug discovery focused companies?
  • What is the likely valuation / net worth of companies engaged in this domain?
  • What is the likely cost saving potential associated with the use of AI in the drug discovery process?
  • How is the intellectual property landscape for AI-based drug discovery technologies likely to evolve in the foreseen future?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • What is the overall trend of funding and investments within this domain?
  • How is the current and future opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. AI-based Drug Discovery: Overall Market Landscape

5. COMPANY PROFILES: AI-BASED DRUG DISCOVERY PROVIDERS IN NORTH AMERICA
5.1. Chapter Overview
5.2. Atomwise
5.2.1. Company Overview
5.2.2. AI-based Drug Discovery Technology Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. BioSyntagma
5.3.1. Company Overview
5.3.2. AI-based Drug Discovery Technology Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. Collaborations Pharmaceuticals
5.4.1. Company Overview
5.4.2. AI-based Drug Discovery Technology Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. Cyclica
5.5.1. Company Overview
5.5.2. AI-based Drug Discovery Technology Portfolio
5.5.3. Recent Developments and Future Outlook
5.6. InveniAI
5.6.1. Company Overview
5.6.2. AI-based Drug Discovery Technology Portfolio
5.6.3. Recent Developments and Future Outlook
5.7. Recursion Pharmaceuticals
5.7.1. Company Overview
5.7.2. AI-based Drug Discovery Technology Portfolio
5.7.3. Recent Developments and Future Outlook
5.8. Valo Health
5.8.1. Company Overview
5.8.2. AI-based Drug Discovery Technology Portfolio
5.8.3. Recent Developments and Future Outlook

6. COMPANY PROFILES: AI-BASED DRUG DISOCVERY SERVICE PROVIDERS IN EUROPE
6.1. Chapter Overview
6.2. Aiforia Technologies
6.2.1. Company Overview
6.2.2. AI-based Drug Discovery Technology Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Chemalive
6.3.1. Company Overview
6.3.2. AI-based Drug Discovery Technology Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. DeepMatter
6.4.1. Company Overview
6.4.2. AI-based Drug Discovery Technology Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Exscientia
6.5.1. Company Overview
6.5.2. AI-based Drug Discovery Technology Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. MAbSilico
6.6.1. Company Overview
6.6.2. AI-based Drug Discovery Technology Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Optibrium
6.7.1. Company Overview
6.7.2. AI-based Drug Discovery Technology Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Sensyne Health
6.8.1. Company Overview
6.8.2. AI-based Drug Discovery Technology Portfolio
6.8.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: AI-BASED DRUG DISOCVERY SERVICE PROVIDERS IN ASIA PACIFIC
7.1. Chapter Overview
7.2. 3BIGS
7.2.1. Company Overview
7.2.2. AI-based Drug Discovery Technology Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Gero
7.3.1. Company Overview
7.3.2. AI-based Drug Discovery Technology Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Insilico Medicine
7.4.1. Company Overview
7.4.2. AI-based Drug Discovery Technology Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. KeenEye
7.5.1. Company Overview
7.5.2. AI-based Drug Discovery Technology Portfolio
7.5.3. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. AI-based Drug Discovery: Partnerships and Collaborations

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. AI-based Drug Discovery: Funding and Investments

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. AI-based Drug Discovery: Patent Analysis
10.4. AI-based Drug Discovery: Patent Benchmarking
10.5. AI-based Drug Discovery: Patent Valuation

11. PORTER’S FIVE FORCES ANALYSIS
11.1. Chapter Overview
11.2. Methodology and Assumptions
11.3. Key Parameters
11.4. Concluding Remarks

12. COMPANY VALUATION ANALYSIS
12.1. Chapter Overview
12.2. Company Valuation Analysis: Key Parameters
12.3. Methodology
12.4. Company Valuation Analysis: Publisher Proprietary Scores

13. AI-BASED HEALTHCARE INITIATIVES OF TECHNOLOGY GIANTS

14. COST SAVING ANALYSIS

15. MARKET FORECAST

16. CONCLUSION

17. EXECUTIVE INSIGHTS

18. APPENDIX I: TABULATED DATA

19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/oatw30


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Point Fort Fichet, a division of ASSA ABLOY France, Partners with Essence Security to Provide the MyShield Intruder Intervention System to the French Security Market

Published

on

point-fort-fichet,-a-division-of-assa-abloy-france,-partners-with-essence-security-to-provide-the-myshield-intruder-intervention-system-to-the-french-security-market

The ASSA ABLOY subsidiary selected Essence’s advanced active solution after identifying a need among French property owners to have direct, remote control over security
HERZLIYA, Israel, April 16, 2024 /PRNewswire/ — Essence Security, a part of Essence Group, a leading technology group developing and supplying wireless, cloud-based security solutions for homes and businesses, today announced its collaboration with Point Fort Fichet, France’s leading locksmith network and a subsidiary of ASSA ABLOY AB (ASSAB:Stockholm). The partnership aims to distribute and implement Essence’s all-encompassing MyShield connected smoke-generating intruder prevention solution across France. MyShield is available for private properties, retail establishments and small businesses — specifically those dealing with large volumes of tax revenue — to fortify these spaces against intensifying security threats.

 
The rate of break-ins in France rose nationally by 3% in 2023, creating a demand for active intervention security solutions. As the first standalone security smoke device, MyShield is at the forefront of the battle against security threats with its ability to proactively detect and act to ensure swift intervention and minimal risk to property damage. Through this partnership, Point Fort Fichet will offer Essence’s MyShield system as a complement to its portfolio of preventative security solutions, which helps consumers gain control of their security from a smartphone or tablet. Together, Point Fort Fichet and Essence offer customers the ability to take direct action, enhancing safety protocols and providing peace of mind to business owners and residents alike.
“As theft and burglary rates rise, we are excited to partner with Essence Security to provide our customers with direct intervention capabilities to stop intruders in their tracks,” said Frederic Colin, Managing Director of Fichet Division of ASSA ABLOY France. “MyShield complements our high-security offerings by providing property owners, especially those who own small businesses, with an added layer of protection that takes auto-surveillance up a level to auto-action. At Fichet, we aim to address the demand for comprehensive solutions that are redefining the meaning of security, and we’re proud to collaborate with a company like Essence to help us achieve this goal.”
MyShield stands out for its intrusion detection and intervention capabilities through security smoke generation. The award-winning, first-of-its-kind device deploys a veil of harmless yet disorienting smoke that fills a room in 30 seconds, forcing intruders off premises before they can cause harm to people or property. MyShield acts as a ‘first responder,’ significantly narrowing the window of time in which intruders can operate and providing an enhanced level of security to residential and commercial users — particularly advantageous in high-risk environments with lone workers or unoccupied buildings where rapid response is crucial. MyShield provides Point Fort Fichet customers full agency over their residential and retail properties’ security.
“In today’s dynamic security landscape where threats are constantly evolving, it’s not enough to just passively watch; there must be action and intervention.”  said Dr. Haim Amir, CEO and Founder of Essence Group. “Partnering with a security leader like Point Fort Fichet ensures home and business owners in the French market will have direct control in protecting their assets. Together we are building on our combined expertise to deliver a comprehensive service that makes properties all over the country safe and secure.”
Easy-to-install, MyShield’s battery-powered system includes an integrated motion detector, high-definition video camera to eliminate false alarms, voice announcement and rapid action remote smoke deployment. It utilizes cellular IoT networks and can be used as a standalone app-based solution or integrated into existing security systems. The low-maintenance device can be easily moved to ensure properties have 24/7 security on demand for reliable protection.
To access MyShield through Point Fort Fichet, please visit here.
About Essence GroupEssence Group is a global technology leader with a mission to develop and deploy innovative, cloud-based, end-to-end security and healthcare solutions, underpinned by supporting services, that provide peace of mind to users. For over a quarter of a century, Essence has challenged convention by making care and safety both accessible and affordable. With over 75 million connected devices deployed worldwide, Essence helps people to live safer and more independent lives.
For more information: https://www.essence-grp.com/
Follow Essence Group on LinkedIn, Twitter and Facebook
About Point Fort FichetPoint Fort Fichet is the largest network of locksmiths in France, also operating in Spain, Belgium, Switzerland, Italy and Portugal. For more than 50 years, Point Fort Fichet has been France’s leading producer of anti-burglary doors, high security locks and cylinders. Point Fort Fichet protects what matters most.
For more information: https://www.fichet-pointfort.com/
 
Media Contact:Mushkie MeyerHeadline [email protected]:+19143364035
Photo – https://mma.prnewswire.com/media/2388284/Essence_Group_1.jpgLogo – https://mma.prnewswire.com/media/1705604/Essence_Group_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/point-fort-fichet-a-division-of-assa-abloy-france-partners-with-essence-security-to-provide-the-myshield-intruder-intervention-system-to-the-french-security-market-302117910.html

Continue Reading

Artificial Intelligence

HaloWallet Rebrands To Halo: Integrating SocialFi & AI To Revolutionize Social Influence Monetization

Published

on

halowallet-rebrands-to-halo:-integrating-socialfi-&-ai-to-revolutionize-social-influence-monetization

VICTORIA, Seychelles, April 16, 2024 /PRNewswire/ — Today, it is thrilling to announce the official brand upgrade from HaloWallet to Halo (halo.social). This upgrade signifies a significant shift in Halo’s vision and commitment to thriving alongside millions of Halo users worldwide in the SocialFi UBI revolution.

Since its inception in October 2023, Halo has been at the forefront of the SocialFi movement. With the launch of Halo Genesis Pass, it has yielded a remarkable 2,000% return for holders and earned international acclaim from users of more than 100 countries.
Moving forward, Halo’s mission is to disrupt the Web2 monopoly and revolutionize the monetization of social influence while ensuring fair and equitable profit sharing. This mission is accomplished through the integration of AI and Web3 DID.
With funding from KuCoin Ventures, IDG, HashKey, and strategic Web3 partners globally, as well as the financial support of the Cyberport incubation program by the Hong Kong government, Halo is poised for an unprecedented leap forward within the realm of SocialFi.
Halo: Pioneering the SocialFi UBI Revolution
Halo (halo.social) is designed to create a revolutionary monetization layer within the SocialFi field, aiming to establish a new paradigm of Universal Basic Income (UBI) that provides ownership to everyone.
Web2 tech giants have generated immense commercial value. However, their centralized nature has led to many concerns on users’ loss of personal data autonomy and unequal value distribution. With blockchain, users can regain control over their assets, data, and accounts. Halo aims to capitalize on advertisement value while respecting user privacy and consent.
Beyond just advertisement, Halo identifies a crucial avenue for monetization: data value. The AI industry has grown rapidly, but due to vague ownership of data copyrights and a lack of unified regulations, high-quality AI corpus remains scarce. As an innovative Web3 project, Halo provides an innovative solution to address this requirement of AI.
Halo has the ability to acquire both on-chain transactions and social content, surpassing Scale AI with full copyright and user consent. By integrating the power of the community to complete data labeling tasks and implementing decentralized governance, Halo meets the demand for high-quality labeled data in AI, enabling the monetization of user data and ensuring a fair redistribution of business profits.
Jeff Hou, the Head of Halo, stated, “The brand upgrade is not merely a marketing move but a natural progression and evolution in the development of Halo. We are gradually transitioning from being a crypto wallet to becoming a fully-fledged ecosystem within SocialFi. It’s time for everyone to see Halo in a new light. We will lead the new wave of the SocialFi UBI revolution, monetizing users’ social influence through our advanced technology architecture and fantastic partnerships in the industry.”
The SocialFi UBI revolution is at our doorstep, and Halo is at the forefront, ready to unlock new opportunities for users to earn, learn, and socialize in a decentralized and equitable environment.
Looking Ahead
Halo token airdrop is a crucial aspect of our vision, designed to strengthen the bond among all members and foster a more engaged and dynamic Halo community. The largest share of Halo tokens, 35%, will be allocated to community, early adopters and alliance members from KuCoin, Mocaverse & other excellent partners.
As a key indicator, Halo Membership Pass will be available for minting on April 26, operating on a season-based promotion system. We’ve launched exclusive discount code giveaways of the Pass with our esteemed partners. Join now to secure a high-level Pass.
Stay tuned for more updates and information on TGE as we continue to evolve and grow as Halo.
About Halo
Halo (halo.social) is designed to build a revolutionary monetization layer within the SocialFi field. We aim to create a new paradigm of UBI (Universal Basic Income) that grants ownership to everyone. By integrating AI, Web3 DID, and Wallet Aggregator, and implementing decentralized governance, Halo is dedicated to transforming the way social influence is monetized and fostering a system of fair and equitable profit sharing.
Website | X | Discord | Telegram
Photo – https://mma.prnewswire.com/media/2388201/HaloWallet_Rebrands_To_Halo_Integrating_SocialFi___AI_To_Revolutionize.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/halowallet-rebrands-to-halo-integrating-socialfi–ai-to-revolutionize-social-influence-monetization-302117951.html

Continue Reading

Artificial Intelligence

Carbon Accounting Startup Zevero Acquired by LEVELUP to Help Companies in Fight to Reduce Global Carbon Emissions

Published

on

carbon-accounting-startup-zevero-acquired-by-levelup-to-help-companies-in-fight-to-reduce-global-carbon-emissions

The combined company will operate under Zevero brand26 and 27-year-old founders secure multi-million-pound deal following rapid UK growthZevero will expand its specialisms in high-emission food and beverage industry to new industries and geographies with a new global management teamLONDON, April 16, 2024 /PRNewswire/ — Zevero, a decarbonisation platform that empowers companies to reach a net zero future, announced it has been acquired by Singapore-based climate tech startup, LEVELUP. The multi-million-pound deal will see the two companies merge under the Zevero brand and expand operations across Asia, Europe and the U.S., fuelling Zevero’s access to the global $15 billion* carbon accounting market.

Zevero’s innovative software platform uses AI-driven carbon modelling, automated emissions calculations and real-time analytics to help companies within the fast-moving consumer goods (FMCG) industry to accurately measure, manage and reduce their carbon footprint across their entire supply chain. In bringing together these capabilities with LEVELUP’s extensive agriculture industry expertise, the new combined offering will be a powerful tool in the global fight against climate change.
“In just three years, Zevero has proven its ability to provide full-stack carbon accounting to clients in over 13 countries,” said Shigeo Taniuchi, incoming CEO of Zevero – previously of LEVELUP. “Combining Zevero’s strong product foundations and UK market experience with our team’s expertise across Asia will rapidly accelerate our shared mission to become the definitive carbon management solution for businesses worldwide.”
Zevero was founded in 2020 by friends Ben Richardson and George Wade, then both just 23. The pair grew frustrated at how challenging it was for businesses to understand their carbon impact end-to-end. With increasing environmental-focused regulation at the time impacting more and more industries, Ben and George recognised a critical need to digitise the carbon accounting process and make it possible for businesses to see the full picture of their carbon impact throughout each stage of their supply chain. As, only through having this visibility, can businesses make any impactful changes to their operations.
A strong footing in the UK
Zevero initially made its name in the UK carbon accounting market, quickly acquiring customers in the food and beverage industry – such as Brixton Brewery and MOTH, amongst others. Rising consumer demand for environmentally-friendly products and services, increasing regulatory enforcement and consequent supply chain pressures are driving the need for accurate emissions data and credible decarbonisation strategies – both areas in which many companies currently lack the right resources, knowledge and tools.
“Climate change is the biggest threat facing society. For most companies, there are multiple challenges in their way.” said Ben Richardson, Co-Founder of Zevero. “Despite pressure to act, they lack the capabilities to see the full impact of their products on the environment. Without that transparency, it’s impossible to set realistic emission reduction targets and drive meaningful change.”
“Traditionally, calculating corporate emissions has relied on spreadsheets and static PDFs. Zevero makes it easier and more accurate for companies to measure, reduce and report on their carbon emissions in real-time, not just once a year,” said George Wade, Zevero’s other Co-Founder. “Much has been said about brands greenwashing, but what we’re hearing from these businesses is that they actively want to make drastic changes to clean up their supply chains – but up until now they haven’t had the data to make those decisions confidently. Zevero has created a solution for that.”
Through the acquisition, Ben and George will remain actively involved as Co-Founders – together with other Co-Founders, seasoned executive, Shigeo Taniuchi and serial entrepreneur, Yuya Kuratomi – and will be responsible for driving Zevero’s product roadmap and growth initiatives. Zevero’s diverse leadership team will integrate LEVELUP’s extensive presence and network in Asia to accelerate the expansion and impact of Zevero.
Notes to Editors
*https://www.fortunebusinessinsights.com/carbon-accounting-software-market-107292
Media pack can be found here
Media Contacts
Hannah Martin: [email protected]; Jo Cresswell: [email protected] 
About Zevero
Zevero is a leading carbon accounting and decarbonisation platform empowering companies towards a net zero future. Its full-stack software solution leverages AI, automated emissions calculations, supply chain data integrations and real-time analytics to accurately measure and reduce carbon footprints for companies across multiple industries. With an impressive track record of operating in 13 countries and 50 million kgCO2e under management, Zevero is headquartered in London with operations across the UK, Europe, Asia and North America. To learn more, visit https://www.zevero.earth/
About Co-Founders
Benjamin Richardson is a Co-Founder of Zevero, a leading carbon accounting and decarbonisation platform that empowers companies to achieve a net zero future. Zevero’s platform leverages AI to make it more efficient to measure and reduce its supply chain carbon emissions. Before Zevero, Ben started a carbon consultancy helping SMEs in the UK with carbon reporting and reduction.George Wade is a Co-Founder of Zevero, a leading carbon accounting and decarbonisation platform that empowers companies to achieve a net zero future. Zevero’s platform leverages AI to make it more efficient to measure and reduce its supply chain carbon emissions. George started Zevero after working in a waste technology startup whilst studying at the University of Exeter. George also founded the positive climate newsletter, The Grumpy Optimist, in 2020, sharing positive climate news with over 4,000 people each week.Shigeo Taniuchi is a Co-Founder and CEO of LEVELUP Climate Tech and is the CEO of Zevero after the integration. Shigeo is the former CEO of a global life science company and a proven global business executive with more than 25 years of experience in various senior roles, including Head of Europe and China. Having studied at Judge Business School and CISL of the University of Cambridge, Shigeo is leveraging his business and academic expertise to lead the global expansion of Zevero and to continue its contribution to society.Yuya Kuratomi is a Co-Founder of Zevero. Yuya is an award-winning serial entrepreneur with a successful track record of launching a digital startup offering enterprise cyber security platform, which he divested at $173M to GMO Internet Group, one of the leading internet service providers in Japan. Since his relocation to Singapore in 2022, he has launched several startups, including LEVELUP Climate Tech.

View original content:https://www.prnewswire.co.uk/news-releases/carbon-accounting-startup-zevero-acquired-by-levelup-to-help-companies-in-fight-to-reduce-global-carbon-emissions-302117930.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending